诚信认证：
工商注册信息已核实！
快速导航
产品分类
微信二维码
Minisite
QQ号咨询
激酶
Crizotinib
| 品牌 | 厂商性质 | 产地 | 货期 |
|---|---|---|---|
| 阿拉丁 | 生产商 | 上海 | 现货 |
产品参数
| 货号 | CAS号 | 操作 |
|---|---|---|
| C137735-100mg | 877399-52-5 | 询价 |
| C137735-10mg | 877399-52-5 | 询价 |
| C137735-1g | 877399-52-5 | 询价 |
| C137735-250mg | 877399-52-5 | 询价 |
| C137735-500mg | 877399-52-5 | 询价 |
| C137735-50mg | 877399-52-5 | 询价 |
| C137735-5g | 877399-52-5 | 询价 |
产品介绍
属性
| 溶解性 | Soluble in DMSO (25 mg/mL warming), ethanol (25 mg/mL warming), methanol, and chloroform. Insoluble in water. |
| 存贮条件 | 储存温度-20°C |
描述
| 应用 |
A Met inhibitor effective against various cell lines Crizotinib has been used: · to investigate its effects on hepatocyte growth factor receptor (c-Met) expression, proliferation and apoptosis · to block neurotrophic tyrosine kinase receptor type 1 (NTRK1) activity in epithelial cells · to restore sensitivity to erlotinib |
| 产品介绍 | PF-2341066 shows inhibition of Met phosphorylation in mIMCD3 mouse of MDCK canine epithelial cells with an IC50 of 5 nM and 20 nM, respectively, as well as NCI-H69 and HOP92 cells, with an IC50 of 13 nM and 16 nM, respectively. PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion varient of the ALK RTK expressed by the KARPAS299 human anaplastic large-cell lymphoma (ALCL) cell line. PF-2341066 supresses human GTL-16 gastric carcinoma cell growth with an IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with an IC5050 of 30 nM. |
| 生化机理 | 克唑替尼（PF-02341066）是受体酪氨酸激酶。 |
| 别名 | 克里唑替尼;3-[(1R)-1-(2,6-二氯-3-氟苯基)乙氧基]-5-[1-(4-哌啶)-1H-吡唑-4-基]-2-吡啶胺;克唑替尼, （R）-3-[1-（2,6-二氯-3-氟 - 苯基）-乙氧基]-5-（1-哌啶-4-基-1H-吡唑-4-基）-吡啶-2-基胺 ;Xalkori;(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine;PF 2341066, PF-02341066, PF02341066 |
Crizotinib信息由上海阿拉丁生化科技股份有限公司为您提供，如您想了解更多关于Crizotinib报价、型号、参数等信息，欢迎来电或留言咨询。
注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途